

# Shirish Gadgeel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/114995/publications.pdf>

Version: 2024-02-01

17  
papers

5,986  
citations

933447

10  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

8453  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
2	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	9.4	919
3	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021, 16, 140-150.	1.1	95
4	Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER) & Medicare investigation of treatment patterns and overall survival. <i>Clinical Epidemiology</i> , 2016, Volume 8, 743-750.	3.0	91
5	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 760-770.	2.1	50
6	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 259-268.	1.1	29
7	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017, 82, 27-33.	2.8	25
8	Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones. <i>Frontiers in Oncology</i> , 2015, 5, 238.	2.8	18
9	Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. <i>Translational Oncology</i> , 2014, 7, 400-409.	3.7	15
10	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
11	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	2.6	12
12	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. <i>Lung Cancer</i> , 2021, 155, 53-60.	2.0	8
13	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101556.	3.4	4
14	Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2022, 17, 187-192.	3.6	3
15	Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189. , 2021, , .		2
16	Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT504-CT504.	0.9	2
17	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 35.	2.7	0